Yoneda Kazue, Imanishi Naoko, Ichiki Yoshinobu, Tanaka Fumihiro
Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health, Japan, Iseigaoka 1-1, Yahata-nishi-ku, Kitakyushu, 807-8555, Japan.
Surg Today. 2019 Jan;49(1):1-14. doi: 10.1007/s00595-018-1659-2. Epub 2018 Apr 11.
A tissue biopsy is the "golden standard" for molecular profiling that is essential in decision-making regarding treatment for malignant tumors, including primary lung cancer. However, tumor biopsies are associated with several limitations, including invasiveness and difficulty in achieving access. Liquid biopsies have several potential advantages over tissue biopsies, and recent advances in molecular technologies have enabled liquid biopsies to be introduced into daily clinical practice. Cell-free blood-based liquid biopsies to detect mutations in the epidermal growth factor receptor (EGFR) gene in the plasma have been approved and may be useful in selecting patients for treatment with tyrosine kinase inhibitors of EGFR. We herein describe blood-based liquid biopsies and review the current status and future perspectives of plasma genotyping in primary lung cancer.
组织活检是分子谱分析的“金标准”，在包括原发性肺癌在内的恶性肿瘤治疗决策中至关重要。然而，肿瘤活检存在一些局限性，包括侵入性和获取样本的困难。液体活检相对于组织活检具有若干潜在优势，并且分子技术的最新进展已使液体活检能够引入日常临床实践。用于检测血浆中表皮生长因子受体（EGFR）基因突变的基于无细胞血液的液体活检已获批准，可能有助于选择接受EGFR酪氨酸激酶抑制剂治疗的患者。我们在此描述基于血液的液体活检，并综述原发性肺癌血浆基因分型的现状和未来前景。
